Efficacy and Safety of Latanoprost versus Travoprost for Primary Open-angle Glaucoma and Ocular Hypertension: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 QIAN ZhiGang ¹ , KE Min ² , HUANG Gang ¹ , ZOU Juan ¹

1. Department of Ophthalmology, Xiangyang Center Hospital, Xiangyang 441021, China;2. Department of Ophthalmology, ZhongNan Hospital of Wuhan University, Wuhan 430071, China;

Corresponding author：

QIAN ZhiGang, Email: moneydcc@yahoo.com.cn

Keywords：

Latanoprost; Travoprost; Primary open-angle glaucoma; Ocular hypertension; Efficacy; Safety; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.20110161

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the efficacy and safety of latanoprost versus travoprost for primary open-angle glaucoma (OAG) and ocular hypertension (OH).
Methods 　All the randomized controlled trials (RCTs) about treating primary open-angle glaucoma and ocular hypertension with latanoprost and travoprost were collected by searching MEDLINE, EMbase, OVID and CNKI. The assessment of methodological quality and data extraction of the included studies were performed independently by two reviewers, and the meta-analysis was conducted with RevMan 5.0 software.
Results 　A total of 13 RCTs involving 1 433 patients were included. The results of meta-analyses showed that, a) At the second week, travoprost showed greater intraocular pressure (IOP) lowering efficacy compared with latanoprost (WMD= –1.47, 95%CI –2.62 to –0.33). At the first month (WMD= –0.50, 95%CI –1.52 to 0.52) and the sixth month (WMD= –0.12, 95%CI –0.85 to 0.61), the difference of IOP reduction between latanoprost and travoprost group was not significant; and b) The latanoprost-treated group showed fewer reported conjunctival congestion than the travoprost-treated group (OR=0.47, 95%CI 0.35 to 0.63). The difference in adverse events of eye pain (OR=0.55, 95%CI 0.27 to 1.12) and iris or skin depigmentation (OR=1.25, 95%CI 0.53 to 2.92) between latanoprost and travoprost group was not significant.
Conclusion 　Latanoprost and travoprost are comparable in lowering IOP for OAG and OH patients. Latanoprost shows greater ocular tolerability with lower incidence of side effects as conjunctival congestion. This conclusion is not powerful enough in proof due to the medium methodology quality of the included studies, so a large number of high-quality RCTs with large sample are needed for objectively, entirely and precisely evaluating the efficacy.

Citation： QIAN ZhiGang,KE Min,HUANG Gang,ZOU Juan. Efficacy and Safety of Latanoprost versus Travoprost for Primary Open-angle Glaucoma and Ocular Hypertension: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2011, 11(8): 965-970. doi: 10.7507/1672-2531.20110161 Copy

1.	1 Higginbotham EJ, Schuman JS, Goldberg I, et al . One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol , 2002, 120(10): 1286-1293.
2.	Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, sixmonth clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol , 2000, 10(2): 95-104.
3.	Netland PA, Landry T, Sullivan EK, et al . Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol , 2001, 132(4): 472-484.
4.	van der Valk R, Webers CA, Schouten JS, et al . Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology , 2005, 112(7): 1177-1185.
5.	McKee HD, Gupta MS, Ahad MA, et al . First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye , 2005, 19(8): 923-924.
6.	Parrish RK, Palmberg P, Sheu WP, et al . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol , 2003, 135(5): 688-703.
7.	孔祥梅,孙兴怀,孟樊荣. 曲伏前列素滴眼液(速为坦)治疗原发性开角型青光眼和高眼压症的临床研究. 中国实用眼科杂志, 2004, 22(11): 877-880.
8.	Dubiner HB, Sircy MD, Landry T, et al . Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther , 2004, 26(1): 84-91.
9.	Orzalesi N, Rossetti L, Bottoli A, et al . Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology , 2006, 113(2): 239-246.
10.	Parmaksiz S, Yüksel N, Karabas VL, et al . A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol , 2006, 16(1): 73-80.
11.	Garcia-Feijoo J, Martinez-de-la-Casa JM, Castillo A, et al . Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin , 2006, 22(9): 1689-1697.
12.	Chen MJ, Chen YC, Chou CK, et al . Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther , 2006, 22(6): 449-454.　.
13.	Hepsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye , 2007, 21(4): 453-458.
14.	Koz OG, Ozsoy A, Yarangumeli A, et al . Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand , 2007, 85(8): 838-843.
15.	Maul E, Carrasco FG, Costa VP, et al . A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther , 2007, 29(9): 1915-1923.
16.	Chiselita D, Antohi I, Medvichi R, et al . Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia , 2005, 49(3): 39-45.
17.	Whitson JT, Trattler WB, Matossian C, et al . Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther , 2010, 26(3): 287-292.

1. 1 Higginbotham EJ, Schuman JS, Goldberg I, et al . One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol , 2002, 120(10): 1286-1293.
2. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, sixmonth clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol , 2000, 10(2): 95-104.
3. Netland PA, Landry T, Sullivan EK, et al . Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol , 2001, 132(4): 472-484.
4. van der Valk R, Webers CA, Schouten JS, et al . Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology , 2005, 112(7): 1177-1185.
5. McKee HD, Gupta MS, Ahad MA, et al . First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye , 2005, 19(8): 923-924.
6. Parrish RK, Palmberg P, Sheu WP, et al . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol , 2003, 135(5): 688-703.
7. 孔祥梅,孙兴怀,孟樊荣. 曲伏前列素滴眼液(速为坦)治疗原发性开角型青光眼和高眼压症的临床研究. 中国实用眼科杂志, 2004, 22(11): 877-880.
8. Dubiner HB, Sircy MD, Landry T, et al . Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther , 2004, 26(1): 84-91.
9. Orzalesi N, Rossetti L, Bottoli A, et al . Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology , 2006, 113(2): 239-246.
10. Parmaksiz S, Yüksel N, Karabas VL, et al . A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol , 2006, 16(1): 73-80.
11. Garcia-Feijoo J, Martinez-de-la-Casa JM, Castillo A, et al . Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin , 2006, 22(9): 1689-1697.
12. Chen MJ, Chen YC, Chou CK, et al . Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther , 2006, 22(6): 449-454.　.
13. Hepsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye , 2007, 21(4): 453-458.
14. Koz OG, Ozsoy A, Yarangumeli A, et al . Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand , 2007, 85(8): 838-843.
15. Maul E, Carrasco FG, Costa VP, et al . A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther , 2007, 29(9): 1915-1923.
16. Chiselita D, Antohi I, Medvichi R, et al . Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia , 2005, 49(3): 39-45.
17. Whitson JT, Trattler WB, Matossian C, et al . Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther , 2010, 26(3): 287-292.

Previous Article
Pemetrexed versus Docetaxel for Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
Next Article
Report Guidelines for Systematic Review and Meta-analysis: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Latanoprost versus Travoprost for Primary Open-angle Glaucoma and Ocular Hypertension: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content